Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 1

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 1
---
Item 3. Key Information

A. [Reserved]

B. Capitalization

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

D. Risk Factors

The following risks relate
specifically to our business and should be considered carefully. Our business, financial condition and results of operations could be
adversely affected by any of the following risks. As a result, the trading price of our ordinary shares and our American Depositary Shares,
or ADSs, could decline and the holders of our ADSs could lose part or all of their investment.

Risks Related to Our Business

  We have a history of operating losses and may         
  not achieve or maintain profitability in the future.  
 ────────────────────────────────────────────────────────

  Our research and development activities could                                  

  We currently have no source of product revenue  
  and may never become profitable.                
 ──────────────────────────────────────────────────

  We will require additional financing and may                                                                                             
  be unable to raise sufficient capital, which could have a material impact on our research and development programs or commercialization  
  of our drug candidates.                                                                                                                  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We may find it difficult to enroll patients in                                                                                            
  our clinical trials, and patients could discontinue their participation in clinical trials, which could delay or prevent clinical trials  
  and make those trials more expensive to undertake.                                                                                        
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Any failure to implement our business strategy                                        

  Positive results from preclinical studies of                                                                             

  Ongoing and future clinical trials of drug candidates                                                      
  may not show sufficient safety and efficacy to obtain requisite regulatory approvals for commercial sale.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If we do not obtain the necessary regulatory                        

  Even if our drug candidates receive regulatory                                                                                
  approval it may still face development and regulatory difficulties that may delay or impair future sales of drug candidates.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We have limited manufacturing experience with  

  To the extent we rely significantly on contractors,                                                 

  We depend on, and will continue to depend on,                                                                                               

  Because we rely on third party manufacturing                                                                                                   
  and supply partners,